Sacha Rothschild - Academia.edu (original) (raw)

Uploads

Papers by Sacha Rothschild

Swiss Medical Weekly

ABSTRACT

European Heart Journal - Case Reports

Background Immune checkpoint inhibitors (ICIs) have markedly improved outcome in various types of... more Background Immune checkpoint inhibitors (ICIs) have markedly improved outcome in various types of cancer. ICI-associated myocarditis is one of the most severe immune-related adverse events. In particular, high concentrations of cardiac troponin T (cTnT) are associated with a high risk of death and early detection and vigorous therapy with high-dose steroids may improve survival. However, chronic skeletal muscle disorders have been suggested as a non-cardiac source of elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations. Case summary Here, we present the case of a 72-year-old patient with metastatic melanoma treated with nivolumab and ipilimumab, who developed symptomatic myositis [creatine kinase (CK) max. 3113 U/L]. Due to substantially elevated concentrations of hs-cTnT (max. 1128 ng/L, normal <14 ng/L, Elecsys), the patient was referred to the cardio-oncology unit for evaluation of concomitant myocarditis. The patient did not report any cardiac symptoms and th...

Journal of Clinical Oncology

9078 Background: ROS1 rearrangements are found in approximately 1% of non-small cell lung cancer ... more 9078 Background: ROS1 rearrangements are found in approximately 1% of non-small cell lung cancer (NSCLC) patients. Prospective clinical trials showed high efficacy of crizotinib in this molecular subset. Lately, we reported an overall response rate (ORR) of 70% and a median progression-free survival (PFS) of 19.4 months for patients treated within the EUCROSS trial (Michels et al. Clin Oncol, 37(15_suppl):9066-9066, 2019). Here we present an updated analysis of the overall survival. Methods: EUCROSS is a European multi-centre, single arm phase 2 trial (Clinicaltrial.gov identifier: NCT02183870). Key eligibility criteria were ≥18 years of age, advanced/metastatic lung cancer, centrally confirmed ROS1-rearranged (fluorescence-in situ hybridisation) and no or stable brain metastases at baseline. Crizotinib was given at a dose of 250 mg twice daily. Primary endpoint of the trial was investigator-assessed ORR in the response-evaluable population (Response Evaluation Criteria in Solid Tum...

Laboratory studies. Data on differential blood counts, renal function, liver function tests and t... more Laboratory studies. Data on differential blood counts, renal function, liver function tests and thyroid function during each treatment cycle (dacarbazine, ipilimumab, nivolumab) are provided. (DOCX 16 kb)

Antibodies and staining protocols. All stains were performed on a Leica BOND III / max autostaine... more Antibodies and staining protocols. All stains were performed on a Leica BOND III / max autostainer platform (Leica Bioystems, Muttenz, Switzerland). Information on antibody clones, pretreatment and staining protocols is provided. (DOCX 18 kb)

Autoimmune serology. Table showing the screening results of autoimmune serology including systemi... more Autoimmune serology. Table showing the screening results of autoimmune serology including systemic antibodies, anti-neutrophil cytoplasmic antibodies (ANCA) and anti-neuronal antibodies. (DOCX 16.8 kb)

Einleitung: Vor dem Hintergrund neuer, immunologischer Therapieansätze kommt der Immunologie in K... more Einleitung: Vor dem Hintergrund neuer, immunologischer Therapieansätze kommt der Immunologie in Kopf-Hals-Karzinomen ein gesteigertes Interesse zu. Es ist zunehmend klar, dass T-Zellen bei der Abwehr, aber auch der Progression von Malignomen eine Rolle spielen. In dieser Studie zeigen wir eine [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Authors' original file for figure 5

Authors' original file for figure 4

Authors' original file for figure 1

Einleitung: Dem Immunsystem kommt eine wichtige Rolle bei der Bekämpfung, aber auch dem Progress ... more Einleitung: Dem Immunsystem kommt eine wichtige Rolle bei der Bekämpfung, aber auch dem Progress maligner Erkrankungen zu. Welche Rolle B-Zellen hierbei spielen, ist bisher nur unzureichend geklärt. Es wird vermutet, dass es, abhängig beispielsweise von der Zusammensetzung des B-Zell-Infiltrats,[zum vollständigen Text gelangen Sie über die oben angegebene URL]

Example SwissMTB clinical report. (PDF 212 kb)

PLOS ONE, 2021

Background and objectives Brain metastases occur in about 30% of all patients with non-small cell... more Background and objectives Brain metastases occur in about 30% of all patients with non-small cell lung cancer (NSCLC). In selected patients, long-term survival can be achieved by resection of brain metastases. In this retrospective study, we investigate the prognosis of NSCLC patients with resected brain metastases and possible prognostic factors. Methods In 119 patients with NSCLC and resected brain metastases, we report the following parameters: extent of resection, resection status, postoperative complications and overall survival (OS). We used the log-rank test to compare unadjusted survival probabilities and multivariable Cox regression to investigate potential prognostic factors with respect to OS. Results A total of 146 brain metastases were resected in 119 patients. The median survival was 18.0 months. Postoperative cerebral radiotherapy was performed in 86% of patients. Patients with postoperative radiotherapy had significantly longer survival (median OS 20.2 vs. 9.0 months...

Swiss Medical Weekly, 2018

BACKGROUND: The majority of germ cell tumour (GCT) patients can be cured by orchiectomy followed ... more BACKGROUND: The majority of germ cell tumour (GCT) patients can be cured by orchiectomy followed by active surveillance or subsequent systemic and/or local treatments. There are various guidelines for a structured follow-up including radiographic and clinical examinations. OBJECTIVE: The Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) prospectively evaluates follow-up, indicator of relapse and late toxicities. This is a descriptive analysis; we present baseline characteristics and treatment strategies for the first 299 patients with primary GCT or relapsed GCT after completion of treatment.

Cancers, 2021

Due to groundbreaking developments and continuous progress, the treatment of advanced and metasta... more Due to groundbreaking developments and continuous progress, the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting, but increasingly challenging task. This applies, in particular, to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged NSCLC with various tyrosine kinase inhibitors (TKIs) is well-established, new targets have been identified in the last few years and new TKIs introduced in clinical practice. Even for KRAS mutations, considered for a long time as an “un-targetable” alteration, promising new drugs are emerging. The detection and in-depth molecular analysis of resistance mechanisms has further fueled the development of new therapeutic strategies. The objective of this review is to give a comprehensive overview on the current landscape of targetable oncogenic alterations in NSCLC.

Info Onkologie, 2011

Die Tumorart und das-stadium entscheiden über die Behandlungsstrategie für Patienten mit einem kl... more Die Tumorart und das-stadium entscheiden über die Behandlungsstrategie für Patienten mit einem kleinzelligen (SCLC) oder nichtkleinzelligen Lungenkarzinom (NSCLC). Neben kurativen sind auch lokale und systemische palliative Ansätze wichtige Bestandteile der Therapie. Sowohl beim "limited disease"als auch beim "extensive disease"-SCLC bildet die Chemotherapie die Hauptsäule der Behandlung.

International Journal of Surgery Case Reports, 2020

INTRODUCTION: Malignant melanoma is a neoplasia with the ability to metastasize to all organs. Mo... more INTRODUCTION: Malignant melanoma is a neoplasia with the ability to metastasize to all organs. Most frequently, metastases derives from a skin primary. A solitary metastasis in the gallbladder is rarely mentioned in current literature. PRESENTATION OF CASE: We present the case of a 62-year-old female patient with the unusual metastatic spread of malignant melanoma into the gallbladder. The lesion was detected during routine follow up appointment six years after the initial surgical and radio-chemotherapeutic treatment of a malignant melanoma on the back. Following multidisciplinary team meeting, it was decided to perform a laparoscopic cholecystectomy to remove the gallbladder metastasis. DISCUSSION: New occurrence of a melanoma metastasis in the gallbladder is extremely rare, especially in stable disease. The therapeutical concept must be discussed extensively in the present of this metastasized tumor. CONCLUSION: In otherwise stable disease, palliative surgery for metastasis in the gallbladder is a possible option to prevent biliary complications. In a palliative setting always weigh up the risks and benefits while maintaining the quality of life.

Journal of Clinical Oncology, 2020

9016 Background: For patients (pts) with resectable stage IIIA(N2) non-small cell lung cancer (NS... more 9016 Background: For patients (pts) with resectable stage IIIA(N2) non-small cell lung cancer (NSCLC) neoadjuvant chemotherapy (chemo) with 3 cycles cisplatin (cis)/docetaxel (doc) followed by surgery is an accepted standard of care leading to a 1-year (yr) event-free survival (EFS) of 48% and a 5-yr overall survival (OS) of 37%. PD-1/PD-L1 inhibitors have recently shown to lead to high response rates in resectable NSCLC. Methods: SAKK 16/14 is an open-label single-arm phase II study including 68 pts with resectable NSCLC stage IIIA(N2) (T1-3 N2 M0), irrespective of histological subtype, genomic aberrations or PD-L1 expression status. Neoadjuvant treatment consisted of 3 cycles of cis 100 mg/m2 and doc 85 mg/m2 q3w followed by 2 cycles of durvalumab 750 mg q2w. Durvalumab was continued after surgery q2w for 1 yr. The primary endpoint is EFS at 1 yr. The statistical hypothesis is to improve EFS at 1 yr from 48% based on the SAKK 16/00 study to 65%. Here, we report the primary endpoin...